Effects of treatment with the antioxidant α-lipoic acid on cardiac autonomic neuropathy in NIDDM patients: A 4-month randomized controlled multicenter trial (DEKAN study)

Diabetes Care

Volumn 20, Issue 3, 1997, Pages 369-373

  Ziegler, Dan ^a   Schatz, Helmut ^d   Conrad, Frank ^b   Gries, F Arnold ^a   Ulrich, Heinz ^b   Reichel, Gerhard ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ASTA MEDICA AG   (Germany)

^c Paracelsus Klinik   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; GLYCOSYLATED HEMOGLOBIN; THIOCTIC ACID;

ADULT; AGED; ARTICLE; AUTONOMIC NEUROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART RATE VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; POWER SPECTRUM; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0031028636     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.3.369     Document Type: Article

References (31)

1. Ziegler D, Gries FA, Mühlen H, Rathmann W, Spüler M, Lessmann F, the DiaCAN Multicenter Study Group: Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. Diabete Metab 19:143-151, 1993
2. Stephenson J, Fuller JH, EURODIAB IDDM Complications Study Group: Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study Diabetologa 37:278-285, 1994
3. Ziegler D, Mayer P, Mühlen H, Gries FA: The natural history of somatosensory and autonomie nerve dysfunction in relation to glycaemic control during the first 5 years after diagnosis of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 34:822-829, 1991
4. Töyry JP, Niskanen LK, Mäntysaari MJ, Länsimies EA, Uusitupa MIJ: Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM: 10-year follow-up from the diagnosis. Diabetes 45:308-315, 1996
5. Ziegler D: Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis, and treatment. Diabetes Metab Rev 10:339-383, 1994
6. Algra A, Tijssen J GP, Roelandt J RTC, Pool J, Lubsen J: Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden death. Circulation 88:180-185, 1993
7. The Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 122:561-568, 1995
8. Kennedy WR, Navarro X, Goetz FC, Sutherland DER, Najarian JS: Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 322:1031-1037, 1990
9. Ziegler D, Dannehl K, Wiefels K, Gries FA: Differential effects of near-normoglycaemia for 4 years on somatic nerve dysfunction and heart rate variation in type 1 diabetic patients. Diabet Med 9:622-629, 1992
10. Cameron NE, Cotter MA: The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 10:189-224, 1994
11. Faes TJC, Yff GA, DeWeerdt O, Lanting P, Hermans JJ, Bertelsmann FW: Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor. J Neurol 240:156-160, 1993
12. Boland OM, Blackwell CC, Clarke BF, Ewing DJ: Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomie function in patients with diabetes mellitus. Diabetes 42:336-340, 1993
13. Giugliano D, Marfella R, Quatraro A, De Rosa N, Salvatore T, Cozzolino D, Ceriello A, Torella R: Tolrestat for mild diabetic neuropathy: a 52-week, randomized, placebocontrolled trial. Ann Intern Med 118:7-11, 1993
14. Giugliano D, Acampora R, Marfella R, Di Maro G, De Rosa N, Misso L, Ceriello A, Quatraro A, D'Onforio F: Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care 18:536-541, 1995
15. Schmidt RE, Dorsey DA, Beaudet LN, Reiser KM, Williamson JR, Tilton RG: Effect of aminoguanidine on the frequency of neuroaxonal dystrophy in the superior mesenteric sympathetic autonomie ganglia of rats with streptozocin-induced diabetes. Diabetes 45:284-290, 1996
16. Moore MV, Jeffcoate WJ, Macdonald IA: Apparent improvement in diabetic autonomic neuropathy induced by captopril. J Hum Hypertens 1:161-165, 1987
17. Low PA, Nickander KK: Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 40:873-877, 1991
18. Suzuki YJ, Tsuchiya M, Packer L: Thioctic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species. Free Radic Res Commun 15:255-263, 1991
19. Nagamatsu M, Nickander KK, Schmelzer JD, Raya A, Wittrock DA, Tritschler H, Low PA: Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18:1160-1167, 1995
20. Ziegler D, Hanefeld M, Ruhnau KJ, Meißner HP, Lobisch M, Schütte K, Gries FA, The ALADIN Study Group: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid: a 3-week randomized controlled trial (ALADIN Study). Diabetologia 38:1425-1433, 1995
21. Ziegler D, Laux G, Dannehl K, Spüler M, Mühlen H, Mayer P, Gries FA: Assessment of cardiovascular autonomie function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet Med 9:166-175, 1992
22. Berger RD, Akselrod S, Gordon D, Cohen RJ: An efficient algorithm for spectral analysis of heart rate variability. IEEE Trans Biomed Eng 33:900-904, 1986
23. Sheiner LB, Rubin DB: Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther 57:6-15, 1995
24. Reschke B, Zeuzem S, Rosak C, Petzoldt R, Althoff P-H, Ulrich H, Schöffling K: Hochdosierte Langzeitbehandlung mit Thioctsäure bei der diabetischen Polyneuropathie: Ergebnisse einer kontrollierten, randomisierten Studie unter besonderer Berücksichtigung der autonomen Neuropathie. In Neue biochemische, pharmakologische und klinische Erkenntnisse zur Thioctsäure. Borbe HO, Ulrich H, Eds. Frankfurt, PMI Verlag, 1989, p. 318-334
25. Kihara M, Low PA: Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy. Exp Neurol 132:180-185, 1994
26. Marfella R, Verrazzo G, Acampora R, La Marca C, Giunta R, Lucarelli C, Paolisso G, Ceriello A, Giugliano D: Glutathione reverses systemic hemodynamic changes induced by acute hyperglycemia in healthy subjects. Am J Physiol 268:E1167-E1173, 1995
27. Rösen P, Ballhausen T, Bloch W, Addicks K: Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: influence of tocopherol as antioxidant. Diabetologia 38:1157-1168, 1995
28. Strödter D, Lehmann E, Lehmann U, Tritschler H-J, Bretzel RG, Federlin K: The influence of thioctic acid on metabolism and function of the diabetic heart. Diabetes Res Clin Pract 29:19-26, 1995
29. Flapan AD, Nolan J, Neilson JMM, Ewing DJ: Effect of captopril on cardiac parasympathetic activity in chronic cardiac failure secondary to coronary artery disease. Am J Cardiol 69:532-535, 1992
30. Bland JM, Altman DG: Some examples of regression towards the mean. BMJ 309:780, 1994
31. Vanninen E, Uusitupa M, Länsimies E, Siitonen O, Laitinen J: Effect of metabolic control on autonomic function in obese patients with newly diagnosed type 2 diabetes. Diabet Med 10:66-73, 1993